Ganirelix Acetate (Ganirelix Acetate) Patent Expiration, LOE Window & CMS Spending

Ganirelix Acetate (Ganirelix Acetate) by Organon: Off-Patent Genericized (AB Competition), 2 AB generics, $34K 2024 CMS Part D & Medicaid spend, and $216 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOrganon
FDA Application & PathwayN021057 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$34K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$34K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($216 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Organon across sibling Meru public-data platforms.